Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111696 · ClinicalTrials.gov registry record · Phase 1
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
A Phase 1 study of Malignant Melanoma, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00111696: Completed Phase 1 study of Malignant Melanoma, sponsored by MedImmune.
NCT00111696 is a Phase 1 study of Malignant Melanoma that has completed, run by MedImmune. The registered enrollment target is 18 participants, below the 183-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00111696, a Phase 1 study of Malignant Melanoma, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.
Conditions Studied
Interventions
- BIOLOGICAL MEDI-522
Study Locations (1)
Pennsylvania
- University Of Pittsburgh Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
What the finished NCT00111696 record still lists
NCT00111696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 183-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 1 intervention - of which MEDI-522 is the first listed.
NCT00111696 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00111696 about?
NCT00111696 is a clinical study titled "Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma". To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.
What is the current status of trial NCT00111696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2005-05. Estimated completion is 2007-11.
What conditions does trial NCT00111696 study?
This clinical trial studies the following conditions: Malignant Melanoma.
What interventions are being tested in trial NCT00111696?
The interventions under investigation include: MEDI-522 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00111696?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00111696 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00111696's enrollment target sits among peer trials
18 23rd of 28 higher than 6 of 28 other Malignant Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
-
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RECRUITING · Phase 1
-
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia